Jacob Johnson
Stock Analyst at Stephens & Co.
(2.85)
# 1,394
Out of 5,182 analysts
78
Total ratings
45.76%
Success rate
8.57%
Average return
Main Sectors:
Stocks Rated by Jacob Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STE STERIS | Reiterates: Overweight | $240 | $222.19 | +8.02% | 7 | Feb 6, 2025 | |
| MASS 908 Devices | Reiterates: Overweight | $6 | $6.74 | -10.98% | 4 | Jan 15, 2025 | |
| LFCR Lifecore Biomedical | Reiterates: Equal-Weight | $6 | $5.08 | +18.11% | 5 | Jan 3, 2025 | |
| AZTA Azenta | Reiterates: Overweight | $60 | $25.15 | +138.57% | 6 | Jan 2, 2025 | |
| DHR Danaher | Reiterates: Overweight | $315 | $180.62 | +74.40% | 2 | Oct 23, 2024 | |
| TMO Thermo Fisher Scientific | Initiates: Overweight | $680 | $468.04 | +45.29% | 1 | Oct 1, 2024 | |
| RGEN Repligen | Reiterates: Overweight | $170 | $118.29 | +43.71% | 4 | Jul 30, 2024 | |
| TKNO Alpha Teknova | Reiterates: Overweight | $5 | $3.14 | +59.24% | 5 | Jul 10, 2024 | |
| MXCT MaxCyte | Reiterates: Overweight | $11 | $0.87 | +1,159.16% | 5 | Apr 23, 2024 | |
| STVN Stevanato Group | Reiterates: Overweight | $38 | $16.18 | +134.86% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $10.38 | +63.78% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.5 | $1.98 | +26.26% | 3 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $87 | $55.11 | +57.87% | 10 | Feb 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $390 | $302.20 | +29.05% | 8 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $16 → $18 | $8.61 | +109.06% | 5 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $2.65 | +126.42% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $29 | $21.41 | +35.45% | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $153 → $130 | $241.79 | -46.23% | 2 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $377 | $171.23 | +120.17% | 1 | Apr 7, 2022 |
STERIS
Feb 6, 2025
Reiterates: Overweight
Price Target: $240
Current: $222.19
Upside: +8.02%
908 Devices
Jan 15, 2025
Reiterates: Overweight
Price Target: $6
Current: $6.74
Upside: -10.98%
Lifecore Biomedical
Jan 3, 2025
Reiterates: Equal-Weight
Price Target: $6
Current: $5.08
Upside: +18.11%
Azenta
Jan 2, 2025
Reiterates: Overweight
Price Target: $60
Current: $25.15
Upside: +138.57%
Danaher
Oct 23, 2024
Reiterates: Overweight
Price Target: $315
Current: $180.62
Upside: +74.40%
Thermo Fisher Scientific
Oct 1, 2024
Initiates: Overweight
Price Target: $680
Current: $468.04
Upside: +45.29%
Repligen
Jul 30, 2024
Reiterates: Overweight
Price Target: $170
Current: $118.29
Upside: +43.71%
Alpha Teknova
Jul 10, 2024
Reiterates: Overweight
Price Target: $5
Current: $3.14
Upside: +59.24%
MaxCyte
Apr 23, 2024
Reiterates: Overweight
Price Target: $11
Current: $0.87
Upside: +1,159.16%
Stevanato Group
Mar 25, 2024
Reiterates: Overweight
Price Target: $38
Current: $16.18
Upside: +134.86%
Mar 13, 2024
Reiterates: Equal-Weight
Price Target: $17
Current: $10.38
Upside: +63.78%
Mar 7, 2024
Reiterates: Equal-Weight
Price Target: $2.5
Current: $1.98
Upside: +26.26%
Feb 2, 2024
Maintains: Overweight
Price Target: $92 → $87
Current: $55.11
Upside: +57.87%
Oct 27, 2023
Maintains: Overweight
Price Target: $420 → $390
Current: $302.20
Upside: +29.05%
Aug 21, 2023
Upgrades: Overweight
Price Target: $16 → $18
Current: $8.61
Upside: +109.06%
Jul 21, 2023
Reiterates: Overweight
Price Target: $6
Current: $2.65
Upside: +126.42%
Jul 17, 2023
Maintains: Overweight
Price Target: $27 → $29
Current: $21.41
Upside: +35.45%
May 16, 2022
Maintains: Overweight
Price Target: $153 → $130
Current: $241.79
Upside: -46.23%
Apr 7, 2022
Initiates: Overweight
Price Target: $377
Current: $171.23
Upside: +120.17%